Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1WO
|
|||
| Former ID |
DCL000548
|
|||
| Drug Name |
ISIS 113715
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Therapeutic Class |
Antisense
|
|||
| Company |
ISIS
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet. 2006;45(8):789-801. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.